Quantcast

Latest Valeant Pharmaceuticals International Inc. Stories

2014-08-15 16:24:18

LAVAL, Quebec, Aug. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan, Inc. ("Allergan") (NYSE: AGN) to 5:00 p.m., New York City time, on December 31, 2014. The exchange offer was previously scheduled to expire at 5:00 p.m., New York City time today, Friday, August 15, 2014. All other terms and conditions of the exchange offer...

2014-08-11 20:24:49

QUEBEC, Aug. 11, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced that the Company has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Valeant's proposed acquisition of Allergan, Inc. (NYSE: AGN). The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). The effect of the second request is to...

2014-08-06 16:28:46

ISS Raises Significant Concerns about Corporate Governance Practices at Allergan LAVAL, Quebec and NEW YORK, Aug. 6, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX: VRX) and Pershing Square Capital Management, L.P. ("Pershing Square") today commented on Institutional Shareholder Services' ("ISS") recommendation in support of Pershing Square's effort to call a special meeting of Allergan shareholders. Pershing Square is seeking to call a special...

2014-08-01 16:23:51

Desperate Allergan Attempt to Interfere with the Special Meeting LAVAL, Quebec and NEW YORK, Aug. 1, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. today responded to the filing of a federal lawsuit by Allergan, Inc. (NYSE: AGN) in California. The complaint makes baseless claims about Valeant and Pershing Square regarding the tender offer rules. Allergan's true purpose in bringing the litigation is an attempt to...

2014-07-31 08:34:07

LAVAL, Quebec, July 31, 2014 /PRNewswire/ -- -- 2014 Second Quarter Total Revenue $2.0 billion; an increase of 86% over the prior year -- Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% -- 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, an increase of 43% -- 2014 Second Quarter GAAP Operating Cash Flow $376 million;...

2014-07-24 08:33:41

LAVAL, Quebec, July 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX:VRX) announced today that it has filed a detailed complaint with the Autorite des marches financiers ("AMF") regarding Allergan, Inc.'s (NYSE: AGN) apparent attempts to mislead investors and to negatively influence the market price of Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements...

2014-07-18 08:24:42

Bausch + Lomb's Organic Growth 12% for the Second Quarter of 2014, over 90% Due to Volume LAVAL, Quebec, July 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has filed an investor presentation with the Securities and Exchange Commission that will be used in meetings with Allergan's institutional investors and proxy advisors, the first of which is being held today, regarding calling a special meeting. The presentation includes a preview...

2014-07-17 08:29:09

VICTUS Platform Offers One of the Largest Arrays of FDA-Cleared Applications for Femto-Assisted Cataract and Refractive Surgery LAVAL, Quebec, July 17, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VICTUS(®) Femtosecond Laser Platform for laser-assisted lens fragmentation* during cataract...

2014-07-14 08:26:41

LAVAL, Quebec, July 14, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan, Inc. (NYSE: AGN). About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty...

2014-07-10 12:29:53

LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma. "We are pleased to complete the divestiture of our products to a company that is...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.